Published • loading... • Updated
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
The deal includes milestone warrants that could lift total proceeds to $24.5 million if shareholders and regulators approve key clinical steps.
- On Friday, Decoy Therapeutics, Inc. announced a $3.5 million private investment in public equity financing, selling common stock at $5.91 per share to a healthcare-focused institutional investor.
- Decoy develops Designable Multi-Antivirals using its proprietary IMPACT platform, and intends to use the net proceeds to advance its lead asset into clinical trials.
- The deal includes milestone-based Series A, B, and C warrants tied to regulatory achievements; Series A targets a Phase 1 application in the European Economic Area, while Series B and C are linked to Phase 2a human challenge trials in the United Kingdom.
- Curvature Securities LLC served as the sole placement agent for the transaction, which is expected to close on or about June 29, 2026, subject to customary closing conditions.
- The warrant structure ties future capital to regulatory progress, positioning Decoy to fund clinical advancement across multiple viral targets as development milestones are achieved and shareholder approvals are obtained.
Insights by Ground AI
45 Articles
45 Articles
charitonleader.com+43 Reposted by 43 other sources
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing
HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that…
·Chariton, United States
Read Full Article
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing - Decoy Therapeutics (NA
HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of
·New York, United States
Read Full ArticleCoverage Details
Total News Sources45
Leaning Left2Leaning Right3Center26Last UpdatedBias Distribution84% Center
Bias Distribution
- 84% of the sources are Center
84% Center
C 84%
Factuality
To view factuality data please Upgrade to Premium
